Ovarian CancerGC-BIONCT01977274
Predictive Clinical and Biological Parameters in Gynecological Cancer
A study testing gynecological cancer in people with Ovarian Cancer and Endometrium Cancer, run by Institut Paoli-Calmettes at 1 site in France.
Trial summary
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- What is being tested?
- gynecological cancer
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- Dec 2013to Dec 2035
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- gynecological cancer suspicion
- age > 18
- signed informed consent
Who cannot join
- emergency
- Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
- Conditions
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- Being tested
- gynecological cancer
- Keywords
- ovarian, endometrium, cervix cancer
- Medical subject headings
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
gynecological cancerOther
blood and tumor samples
| Study group | Role | What they receive |
|---|---|---|
| gynecological cancer | Experimental | blood and tumor samples Receives: Other: gynecological cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
molecular alteration in gynecological cancer
gene expression level
Measured: average of 4 weeks after diagnosis
Secondary outcomes (1)
relation between molecular alteration and clinical and histological characteristics
hazard ratio between molecular alteration and clinico-histological characteristics
Measured: up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2013 (estimated)
- Study startDec 2013
- Primary completionDec 2033 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by Institut Paoli-CalmettesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Paoli-Calmettes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01977274
- Sponsor's protocol ID
- GC-BIO-IPC 2013-010
- Acronym
- GC-BIO
- Status last verified
- Mar 2026
- First submitted
- 30 Oct 2013
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010
- ClinicalTrials.gov ID
- NCT01977274
- Acronym / sponsor ID
- GC-BIO / GC-BIO-IPC 2013-010
- Conditions
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- Keywords
- ovarian, endometrium, cervix cancer
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Institut Paoli-CalmettesUniversity, hospital or other
- Study start
- Dec 2013
- Primary completion
- Dec 2033 (estimated)
- Study completion
- Dec 2035 (estimated)
- First posted
- 6 Nov 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| gynecological cancer | Experimental | Other: gynecological cancerblood and tumor samples |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- gynecological cancer suspicion
- age > 18
- signed informed consent
Key exclusion criteria (2 listed)
- emergency
- Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| gynecological cancerblood and tumor samples | Other | gynecological cancer |
Primary outcome
molecular alteration in gynecological cancer
Time frame: average of 4 weeks after diagnosis
gene expression level
1 secondary outcome
relation between molecular alteration and clinical and histological characteristics
Time frame: up to 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- official web site of the sponsorLink provided by the sponsor.
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing gynecological cancer in people with Ovarian Cancer and Endometrium Cancer, run by Institut Paoli-Calmettes at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
molecular alteration in gynecological cancer (time frame: average of 4 weeks after diagnosis). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.